Navigation Links
Study Confirms Passive Safety Devices Are Most Effective in Needlestick Injury Prevention
Date:10/26/2010

BETHLEHEM, Pa., Oct. 26 /PRNewswire/ -- A landmark study of 22 million safety devices used in 61 French hospitals over a two-year period has confirmed the theory that passive, fully automatic safety devices offer significantly better protection against accidental needlestick injuries (NSIs) than early generation active safety technologies such as semi-automatic (push-button) devices or those with manually sliding shields or hinged caps.

(Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO)

This study, described in the article "Needlestick Injury Rates According to Different Types of Safety-Engineered Devices: Results of a French Multicenter Study" in the April 2010 issue of Infection Control and Hospital Epidemiology, was the first head-to-head comparison of safety-engineered devices by safety technology type. It was conducted by GERES (Groupe d'Etude sur le Risque d'Exposition des Soignants), a well-established, government-funded research group.

The study concludes that passive safety engineered devices are more effective than active devices for NSI prevention.

Among its findings, the study documents the procedure specific needlestick injury rate by safety device technology. For intravascular catheters the NSI rate for passive or fully automatic devices studied was 1.31 per 100,000 devices used, compared with 2.54 per 100,000 devices used for semi-automatic (push-button) technology and 4.34 per 100,000 devices used for manually sliding shield technology. With semi-automatic and sliding shield devices, healthcare workers can choose whether or not to operate the safety features. Passive, fully automatic devices, on the other hand, "require no input from the user" and "eliminate the need for elaborate training." Ac
'/>"/>

SOURCE B. Braun
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
2. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Positive Results From LigoCytes Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
5. Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
6. INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine
7. Despite Potential Risk of Serious Birth Defects, New Study Finds Poor Adherence to Oral Contraception among Women on Category X Medications
8. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
9. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
10. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
11. IDRI Develops Novel Tuberculosis Vaccine, New Study in Science Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... - First of three ongoing randomized chemotherapy combination trials ... HGS-ETR1 in the treatment of specific cancers -, ... HGSI ) today reported initial topline results from,an ... receptor antibody,HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in ...
... This Common and Successful Surgery, ROCHESTER, Minn., ... issue of Mayo Clinic Health Letter. You may,cite ... is allowed for a,fee. Mayo Clinic Health Letter ... your editorial policies permit: Visit, http://www.HealthLetter.MayoClinic.com or ...
Cached Medicine Technology:Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 2Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 3Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 4Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 5Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 6September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 2September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 3September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 4
(Date:12/25/2014)... (PRWEB) December 25, 2014 Parker & ... outstanding customer service and affordable quality regarding heating, cooling ... announces recognition in 2014 by the “Queen of Clean” ... has earned an impressive reputation over the years for ... a wide range of contractor services for both homeowners ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The ... that allege the blood thinner caused life-threatening episodes ... a leadership structure for the proceeding, Bernstein Liebhard ... 17th, the Court plans to select lawyers to ... also plans on appointing a Plaintiffs’ Steering Committee, ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... is Leading Proponent for Single-Payer Healthcare ... Reforms - ,Medicare ... camera on the,fastest-growing union in America -- and the nation,s ... California Nurses,Association/National Nurses Organizing Committee,s fight for guaranteed,single-payer healthcare in ...
... odds of heart attack, death, study finds , , THURSDAY, May ... can hear when passing a stethoscope over a main artery ... attack and death from heart disease and stroke, a new ... (pronounced brew-ee) -- is caused by turbulent blood flow due ...
... 6, 2008) The American Society of Hematology (ASH) ... for its 2008 Minority Medical Student Award Program (MMSAP), ... in hematology research. Under the program, each award recipient ... a career development mentor, travel stipends to attend medical ...
... $0.18 In Line with Previously Announced ... Expectations, ... largest air medical transportation company in the,world, reported financial results for the ... flight volumes. For the quarter,revenue increased 45.0% to $118.1 million from $81.5 ...
... Corporation is launching a,third dental industry-focused online Tradeshow, ... is now open and available at, http://www.ddstechfair.com . ... bring dental professionals together with,colleagues and manufacturers at ... Tech Fair is designed to give the dental ...
... role in development of defective cells in type 2 diabetics ... an important gene during fetal development appears to increase vulnerability ... , Intrauterine growth retardation (IUGR), which causes low birth ... type 2 diabetes and other diseases when a child grows ...
Cached Medicine News:Health News:Bill Moyers' Journal to Feature California Nurses Association/National Nurses Organizing Committee in Friday, May 9th Episode 2Health News:Noise in Artery Could Warn of Heart Risk 2Health News:Minority medical students receive support to increase diversity in hematology 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 3Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 4Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 5Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 6Health News:PennWell Announces DDS Tech Fair 2Health News:Fetal Gene May Contribute to Diabetes Risk 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: